LC/MS/MS Analysis of Impurities in Active Pharmaceutical Ingredients Using the Co-Sense for Impurities System

Significance of the Topic

Impurity profiling in active pharmaceutical ingredients (APIs) is critical for ensuring drug safety, efficacy and regulatory compliance. Effective separation and identification of low‐level impurities prevent adverse patient outcomes and support robust quality control in pharmaceutical production.

Objectives and Study Overview

This study demonstrates the application of a two‐dimensional LC/MS/MS approach using the Co-Sense for Impurities System to isolate, identify and quantify trace impurities in rabeprazole sodium. Key goals include separation of impurities co‐eluting with the main API peak, structural elucidation and enhancement of analytical sensitivity.

Methodology and Instrumentation

The API sample (rabeprazole sodium, 1 mg/mL) was prepared according to the Japanese Pharmacopeia. The Co-Sense for Impurities System employed three chromatographic stages interconnected by switching valves. In the first dimension, gradient HPLC-UV at 290 nm separated the bulk API and impurity fraction, which was directed to a trap column using a volatile mobile phase for MS compatibility. The second dimension concentrated the target fraction on a short STR-ODSⅡ column, followed by final separation on a narrow‐bore Shim-pack XR-ODS column under methanol/ammonium acetate elution. MS/MS detection used electrospray ionization in positive mode with both full‐scan and multiple reaction monitoring (MRM) modes for enhanced selectivity and quantification.

Used Instrumentation

• Co-Sense for Impurities System with valve switching for 2D flow paths
• Shim-pack VP-ODS column (150 × 4.6 mm, 4 µm)
• STR-ODSⅡ trap column (10 × 4.6 mm, 5 µm)
• Shim-pack XR-ODS analytical column (50 × 2.0 mm, 2.2 µm)
• LCMS-8030 triple quadrupole mass spectrometer (ESI+)
• UV detector operating at 290 nm
• Autosampler, binary pumps and column oven (30 °C)

Main Results and Discussion

Initial 1D LC-UV revealed a single impurity peak at RT ≈ 6.8 min, representing 0.06 % of the API area. 2D separation resolved this into three distinct peaks (IM1–IM3), each giving characteristic m/z signals at 394.1, 508.2 and 569.2. Product ion scanning of m/z 508.2 suggested a benzimidazol-2-thiol derivative of the API. MRM assays for IM1–IM3 exhibited excellent linearity (r2 > 0.998) and repeatability (RSD < 2.5 %), confirming robust quantification. Optimization of the second‐dimension mobile phase (acetic acid vs. ammonium acetate buffer) further improved peak resolution and sensitivity.

Benefits and Practical Applications

• Efficient isolation of co-eluting impurities enhances analytical confidence.
• Two‐dimensional workflow increases sensitivity by concentrating trace components.
• MRM quantification provides high specificity for low-level impurity monitoring.
• Approach supports regulatory requirements for impurity identification in pharmaceutical QC.

Future Trends and Opportunities

Integration of high-resolution accurate-mass detection could further improve structural elucidation. Automated 2D-LC workflows and real-time impurity profiling are expected to accelerate method development. Expanding this platform to other APIs and complex drug formulations will enhance routine QC and stability studies.

Conclusion

The Co-Sense for Impurities two-dimensional LC/MS/MS system offers a powerful solution for detailed impurity analysis in APIs, combining improved separation, structural insight and quantitative performance. This methodology enables pharmaceutical laboratories to meet stringent quality standards with greater efficiency and confidence.